Pyxis Oncology presents MICVO data showing 36% confirmed response rate in advanced head and neck cancer
PYXS•Pyxis Oncology reported a 36% confirmed response rate for MICVO monotherapy in 33 evaluable patients with previously treated recurrent or metastatic head-and-neck cancer. Median progression-free survival was 6.2 months, and grade 3 or higher treatment-related adverse events affected 54.3% of 35 patients.
1. Monotherapy results
MICVO monotherapy produced a 36% confirmed response rate in 33 evaluable patients with previously treated recurrent or metastatic head-and-neck cancer. Median progression-free survival was 6.2 months; estimated 12-month overall survival was 79% in the dose-capped subgroup. Grade 3 or higher treatment-related adverse events affected 54.3% of 35 patients, with no treatment-related deaths.
2. Upcoming data and trial
Updated first-line pembrolizumab combination data are expected in December 2026, and monotherapy overall survival data are due in the first half of 2027. Pyxis Oncology said a strengthened balance sheet supports advancement toward the planned Headliner Phase 3 trial.
